Increased levels of advanced oxidation protein products (AOPPs) were associated with nociceptive behavior and clinical scores in an experimental progressive autoimmune encephalomyelitis model (PMS‐EAE)

Multiple sclerosis (MS) is a neurodegenerative disease that affects the central nervous system (CNS) generating neuropathic pain and anxiety. Primary progressive MS (PPMS) is the most disabling clinical form, and the patients present an intense neurodegenerative process. In this context, the advanced oxidation protein products (AOPPs) are oxidized compounds and their accumulation in plasma has been related to clinical disability in MS patients. However, the involvement of AOPPs in neuropathic pain‐ and anxiety‐like symptoms was not previously evaluated. To assess this, female mice C57BL/6J were used to induce progressive experimental autoimmune encephalomyelitis (PMS‐EAE). Clinical score, weight, strength of plantar pressure, rotarod test, mechanical allodynia, and cold hypersensitivity were evaluated before induction (baseline) and on days 7th, 10th, and 14th post‐immunization. We assessed nest building, open field, and elevated plus‐maze tests 13 days post‐immunization. Animals were killed at 14 days post‐immunization; then, AOPPs levels, NADPH oxidase, and myeloperoxidase (MPO) activity were measured in the prefrontal cortex, hippocampus, and spinal cord samples. The clinical score increased 14th post‐immunization without changes in weight and mobility. Reduced paw strength, mechanical allodynia, and cold allodynia increased in the PMS‐EAE animals. PMS‐EAE mice showed spontaneous nociception and anxiety‐like behavior. AOPPs concentration, NADPH oxidase, and MPO activity increase in CNS structures. Multivariate analyses indicated that the rise of AOPPs levels, NADPH oxidase, and MPO activity influenced the clinical score and cold allodynia. Thus, we indicated the association between non‐stimuli painful perception, anxiety‐like, and CNS oxidative damage in the PMS‐EAE model. Primary progressive multiple sclerosis (PPMS) is the most disabling clinical form of multiple sclerosis (MS). The involvement of advanced oxidation protein products (AOPPs) and their accumulation in plasma have been related to clinical disability in MS patients, but has not been evaluated yet in neuropathic pain‐ and anxiety‐like symptoms. Here, we demonstrated an association of rising AOPPs levels with non‐stimulus‐induced painful perception, anxiety‐like behavior, and central nervous system oxidative damage in an experimental autoimmune encephalomyelitis (PMS‐EAE) model using female C57BL/6J mice.